Our ability to inhibit the early inflammatory response (with biological complement and thrombin regulators) will create a more favourable environment for the effective functioning of Treg approaches.

Our emphasis is on ‘second phase’ Treg therapy, i.e. donor-specific cells generated with chimaeric-antigen-receptor (CAR) combined with low dose IL-2 therapy and imaging to detect the fate and traffic of injected cells.

Our strengths defining signatures of tolerance provide surrogate end-points, while our stratification of patients into those more or less likely to become tolerant uses genotyping and immune monitoring.

Lead

Steven Sacks NIHR Senior Investigator FMedSci

Professor of Nephrology, Consultant Physician (clinically active), Director, MRC Centre for Transplantation, Head of Complement-UK